Qube Research & Technologies (QRT)
CATX icon

Qube Research & Technologies (QRT)’s Perspective Therapeutics CATX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.1K Sell
15,608
-65,688
-81% -$278K ﹤0.01% 3137
2025
Q4 		$224K Buy
81,296
+12,337
+18% +$35.2K ﹤0.01% 3029
2025
Q3 		$237K Sell
68,959
-25,734
-27% -$93.8K ﹤0.01% 2906
2025
Q2 		$326K Sell
94,693
-27,320
-22% -$72.1K ﹤0.01% 2805
2025
Q1 		$260K Sell
122,013
-148,440
-55% -$445K ﹤0.01% 2783
2024
Q4 		$863K Buy
+270,453
New +$2.21M ﹤0.01% 2241
2024
Q3 		– Sell
-83,346
Closed -$831K – 3380
2024
Q2 		$831K Buy
83,346
+58,722
+238% +$849K ﹤0.01% 1969
2024
Q1 		$293K Buy
+24,624
New +$210K ﹤0.01% 2830

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CATX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Perspective Therapeutics (CATX) stake by 81% in Q1 2026, selling an estimated $278K and leaving 15,608 shares worth $65.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

Qube Research & Technologies (QRT) first reported a position in CATX in Q1 2024 and has held it in 8 quarters since. The position peaked at $863K in Q4 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Qube Research & Technologies (QRT) held 15,608 shares of Perspective Therapeutics worth $65.1K as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 65,688 Perspective Therapeutics shares in Q1 2026, an estimated $278K.
  • Perspective Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3137 holding.
  • Qube Research & Technologies (QRT) first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Qube Research & Technologies (QRT)'s Perspective Therapeutics position peaked at $863K in Q4 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.